Evidence map›Paper›PMID 32845402›Full record

ReviewCurrent rheumatology reports2020

Promising and Upcoming Treatments in Myositis.

Lauren N Smith, Julie J Paik

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Current rheumatology reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Trial
  2. Past, Present, and Future in Dermatomyositis Therapeutics.Current treatment options in rheumatology · 2022
    Article
  3. A glance into the future of myositis therapy.Therapeutic advances in musculoskeletal disease · 2022
    Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Lauren N SmithJohns Hopkins University School of Medicine, 5200 Eastern Ave, MFL Building, Center Tower Suite 4100, Baltimore, MD, USA.
Julie J PaikJohns Hopkins University School of Medicine, 5200 Eastern Avenue, MFL Building, Center Tower Suite 4500, Baltimore, MD, 21224, USA. jpaik1@jhmi.edu.

Funding

Multidisciplinary Rheumatology Training ProgramT32AR048522 · NIAMS · JOHNS HOPKINS UNIVERSITY · PI CLIFTON O BINGHAM, LIVIA A CASCIOLA-ROSEN · 2003 to 2026
$6.4M
Skeletal Myopathy in Systemic Sclerosis: Devising a Classification Schema Predictive of OutcomesK23AR073927 · NIAMS · JOHNS HOPKINS UNIVERSITY · PI PAIK, JULIE JISUN · 2020 to 2024
$787k
NIAMS NIH HHS K23 AR073927NIAMS NIH HHS T32 AR048522
6 · The paper itself

Abstract

purpose of reviewTo highlight new and emerging treatment targets in myositis. RECENT

findingsThe landscape of novel therapeutics in myositis has vastly changed in the past 5 years. This is largely due to a greater understanding of the pathogenesis of myositis and validation of more robust outcome measures that standardize the ability to assess treatment response. Clinical trials in dermatomyositis are leading the way with ongoing multicenter, international phase 3 clinical trials. Proof-of-concept studies targeting the JAK/STAT pathway have also showed early promise in treating refractory dermatomyositis in adults and children. This review highlights that the future armamentarium of therapeutic drugs will likely be larger and more selective in treating different subgroups of myositis.

Indexed as

DermatomyositisMyositisClinical Trials, Phase III as TopicHumansMulticenter Studies as TopicDermatomyositisImmune-mediated necrotizing myopathyMyositisNovel treatments

Identifiers

PMID32845402
PMCPMC7955788

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.